SILVERARC CAPITAL MANAGEMENT, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001816307

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q4 2025 · 65 positions · Total reported value $659.14M · Top-10 concentration 51.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 15 new · 20 cut · 18 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2025 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 65 equity positions with a combined reported value of $659.14M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 51.6% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were ABVX ($56.93M), COGT ($44.23M), URGN ($40.72M). By sector, the heaviest allocations are Health Care 92.0%, Other 8.0%. Versus the prior quarter, allocation shifted toward Health Care (+12.8pp) and away from Other (-12.4pp).

Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 49% of names.

The largest new positions opened in Q4 2025 were IMNM ($24.19M), PFE ($10.44M), GH ($9.39M).

Of the 18 positions fully exited versus the prior quarter, the largest were RNAM ($36.80M), AKRO ($30.56M), UTHR ($25.11M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • IMNM IMMUNOME INC · $24.19M
  • PFE PFIZER INC · $10.44M
  • GH GUARDANT HEALTH INC · $9.39M
  • SYRE SPYRE THERAPEUTICS INC · $6.15M
  • SLNO SOLENO THERAPEUTICS INC · $5.44M
  • FULC FULCRUM THERAPEUTICS INC · $4.43M
  • SRZN Surrozen Inc · $3.56M
  • RLAY RELAY THERAPEUTICS INC · $3.37M

Fully Exited (vs previous quarter)

  • RNAM AVIDITY BIOSCIENCES INC · prev qtr: $36.80M
  • AKRO AKERO THERAPEUTICS INC · prev qtr: $30.56M
  • UTHR UNITED THERAPEUTICS CORP DEL · prev qtr: $25.11M
  • CDTX CIDARA THERAPEUTICS INC · prev qtr: $21.15M
  • CYTK CYTOKINETICS INC · prev qtr: $11.60M
  • VSTM VERASTEM INC · prev qtr: $9.21M
  • SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $8.71M
  • ALKS ALKERMES PLC · prev qtr: $5.42M · history

Insider Transactions (Form 4)

Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-116845 (status: Approved), registered 2019-06-21
  • Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: silverarccapital.com

Portfolio Structure

  • 67 positions · $855.33M reported value (Q2 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
  • Average position size: $12.77M

Sector Tilt

  • Health Care 98.1%
  • Financials 1.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 92.0%
Other 8.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 422.19K $56.93M 8.64%
8.64%
Reduce
2 1.25M $44.23M 6.71%
6.71%
Add
3 1.74M $40.72M 6.18%
6.18%
Add
4 375.13K $37.42M 5.68%
5.68%
Add
5 311.43K $31.33M 4.75%
4.75%
Reduce
6 750.14K $30.91M 4.69%
4.69%
Add
7 1.02M $28.61M 4.34%
4.34%
Add
8 82.47K $24.31M 3.69%
3.69%
Add
9 1.13M $24.19M 3.67%
3.67%
New
10 9.84M $21.65M 3.28%
3.28%
Reduce
11 1.03M $16.14M 2.45%
2.45%
Add
12 357.56K $15.05M 2.28%
2.28%
Add
13 361.16K $15.00M 2.27%
2.27%
Reduce
14 135.95K $14.55M 2.21%
2.21%
Reduce
15 642.90K $13.51M 2.05%
2.05%
Add
16 75.41K $13.27M 2.01%
2.01%
Reduce
17 71.26K $12.40M 1.88%
1.88%
Reduce
18 458.20K $11.46M 1.74%
1.74%
Add
19 348.57K $10.85M 1.65%
1.65%
Add
20 49.23K $10.50M 1.59%
1.59%
Reduce
21 419.13K $10.44M 1.58%
1.58%
New
22 731.72K $9.86M 1.50%
1.50%
Add
23 524.44K $9.52M 1.45%
1.45%
Reduce
24 91.91K $9.39M 1.42%
1.42%
New
25 1.12M $9.13M 1.39%
1.39%
Reduce
26 148.79K $6.87M 1.04%
1.04%
Reduce
27 541.24K $6.78M 1.03%
1.03%
Reduce
28 2.14M $6.62M 1.00%
1.00%
Reduce
29 187.74K $6.15M 0.93%
0.93%
New
30 617.61K $6.13M 0.93%
0.93%
Reduce
31 506.24K $6.12M 0.93%
0.93%
Reduce
32 2.81M $5.80M 0.88%
0.88%
Add
33 1.05M $5.65M 0.86%
0.86%
Reduce
34 117.48K $5.44M 0.82%
0.82%
New
35 3.48M $5.32M 0.81%
0.81%
Add
36 191.07K $5.19M 0.79%
0.79%
Reduce
37 206.28K $5.16M 0.78%
0.78%
Reduce
38 1.32M $4.90M 0.74%
0.74%
Reduce
39 290.60K $4.69M 0.71%
0.71%
Reduce
40 391.90K $4.43M 0.67%
0.67%
New
41 303.94K $3.99M 0.60%
0.60%
Reduce
42 1.99M $3.81M 0.58%
0.58%
Add
43 157.32K $3.56M 0.54%
0.54%
New
44 307.54K $3.52M 0.53%
0.53%
Add
45 94.98K $3.45M 0.52%
0.52%
Add
46 398.17K $3.37M 0.51%
0.51%
New
47 627.74K $3.31M 0.50%
0.50%
Reduce
48 2.65M $3.12M 0.47%
0.47%
Reduce
49 126.05K $3.02M 0.46%
0.46%
Reduce
50 36.12K $2.96M 0.45%
0.45%
New

FAQ

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2025-Q4?

In its 2025-Q4 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 65 equity positions worth $659.14M in aggregate; its largest disclosed positions were ABVX ($56.93M), COGT ($44.23M), URGN ($40.72M).

How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?

SILVERARC CAPITAL MANAGEMENT, LLC reported $659.14M of long equity holdings across 65 positions as of 2025-Q4. Top-10 holdings account for 51.6% of reported value.

What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/silverarc-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →